产品
编 号：F746184
分子式：C57H66ClF4N6O11PS4
分子量：1281.85
分子式：C57H66ClF4N6O11PS4
分子量：1281.85
产品类型
规格
价格
是否有货
结构图
CAS No: 1619923-36-2
产品详情
生物活性：
Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects.
体内研究：
Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10 days) treatment inhibits xenograft tumor growth more obviously than the other groups.Animal Model:BALB/c athymic nude mice (male, 4-6weeks) injected with N87 cells
Dosage:25 mg/kg, 50 mg/kg, and 100 mg/kg
Administration:Intravenous injection; once a day; for 10 days
Result:Inhibited xenograft tumor growth more obviously than the other groups.
体外研究：
APG-1252 changes to the reactive metabolite named APG-1252-M1, which has remarkable antitumor effects in acute myeloid leukemia.
Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects.
体内研究：
Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10 days) treatment inhibits xenograft tumor growth more obviously than the other groups.Animal Model:BALB/c athymic nude mice (male, 4-6weeks) injected with N87 cells
Dosage:25 mg/kg, 50 mg/kg, and 100 mg/kg
Administration:Intravenous injection; once a day; for 10 days
Result:Inhibited xenograft tumor growth more obviously than the other groups.
体外研究：
APG-1252 changes to the reactive metabolite named APG-1252-M1, which has remarkable antitumor effects in acute myeloid leukemia.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备